Skip to content
Review Open access

From ROS-Responsive Nanosystems to Microbiome Modulation: Advanced Drug Delivery Reshaping Inflammatory Bowel Disease and Chronic Inflammatory Diseases

Sep 2026 · International Journal of Applied Pharmaceutics · 0 citations

Abstract

Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, serves as a compelling model for advanced drug delivery innovation owing to its well-characterised inflammatory microenvironment and significant unmet clinical need. This semi-systematic review evaluated three converging innovation streams in IBD drug delivery research. A structured literature search was conducted across PubMed, Scopus, Web of Science, and ClinicalTrials.gov (January 2015–October 2025). Of 847 records screened, 412 were assessed for full-text eligibility and 199 met predefined inclusion criteria. Evidence was synthesised narratively by thematic stream and graded by study type. Three innovation streams were identified: (1) microenvironment-responsive systems exploiting reactive oxygen species (ROS), pH, and enzymatic triggers; (2) microbiome-targeting therapeutics, including engineered probiotic platforms, postbiotic nanogels, and bacterial derivatives; and (3) biological delivery platforms enabling oral administration of antibodies, nucleic acids, and biomimetic carriers. Key findings include the Glyro thioketal nanosystem achieving less than 1% systemic mesalazine absorption versus approximately 20–30% for free drug [1]; a metal-organic framework (MOF)-based oral anti-tumour necrosis factor-alpha (TNF-α) antibody suppressing mucosal TNF-α by 71% in chronic colitis models [3]; and a closed-loop theranostic microgel reducing TNF-α by 65% and interleukin-6 by 58% [4]. Critically, pH-triggered Eudragit® S100 systems fail in approximately 20–30% of patients with severe disease, and LNP platforms carry uncharacterised complement activation risk on repeated dosing-translational limitations addressed in this review. Design principles derived from IBD research-disease-specific triggering, hierarchical targeting, theranostic monitoring, and scalable manufacturing-provide a translational blueprint for rheumatoid arthritis, type 1 diabetes, and psoriasis. Critical barriers include the absence of clinically approved ROS-responsive systems, inter-patient microenvironmental heterogeneity, manufacturing scalability constraints, and limited long-term human safety data.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.